Publications

Publications

At Bayer, we are working in collaboration with the leading scientific, academic, and community partners to improve our understanding of cardiorenal diseases.  

 

We invite you to explore Bayer-supported publications pertaining to heart failure with a focus on LVEF ≥ 40%. This library is not intended to serve as a comprehensive repository of all publications. Publications not supported by Bayer are not included. Access to the full text of publications may depend on journal access rights.

 

To help narrow down your search, choose the relevant tags and click apply. Applying multiple tags will narrow your results.

 

Last updated April 20, 2026.

Types of Enhancements Available

audio
Audio
infographic
Graphical Abstract
PLS
Plain Language Summary
video
Video
other
Others

To help narrow down your search, select the relevant filters from the dropdowns and Click Apply

Hold down Ctrl key on keyboard to select multiple years

Total available publications: 90    

Filtered results: 90

Effects of Finerenone Across a Range of Heart Failure Duration: A Prespecified Analysis of the FINEARTS-HF Trial

Hamatani Y., et al, EJHF. 2026

Hamatani Y, 05 05 2026

Finerenone, Liver Biomarkers, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: An Analysis of FINEARTS-HF

Butt J., et al, CHF 2026

Butt J, 05 05 2026

Heart Failure and Comorbidities (Chronic Kidney Disease, Diabetes, Obesity) Management: A Multidisciplinary Approach

Abramov D. et al, CRM. 2026

Abramov D, 07 04 2026

Interchangeability of the KCCQ-12 and KCCQ-23 Across >18,000 Participants Enrolled in 4 Large-Scale Trials of Heart Failure

Hamatani Y., et al., JACC. 2026

Hamatani Y, 07 04 2026

Treatment with Finerenone in People with Heart Failure and Mildly Reduced or Preserved Ejection Fraction: A Plain Language Review

Bains M., et al, FC. 2026

Bains M, 07 04 2026

Sex Differences in Cardiovascular–Kidney–Metabolic Syndrome: The FINE-HEART Pooled Analysis

Pablon M., et al, EHJ. 2026

Pabon M, 12 03 2026

Finerenone and Quality of Life in Heart Failure: Component-Level Analyses and Clinical Relevance of the Kansas City Cardiomyopathy Questionnaire

Hamatani Y., et al, EHJ. 2026

Hamatani Y, 11 03 2026

Effects of Finerenone on Heart Failure Outcomes According to Baseline Heart Failure Risk in Chronic Kidney Disease and Type 2 Diabetes

Ostrominski J., et al, JACC. 2026

Ostrominski J, 10 03 2026

EMPEROR-Preserved Risk Model and Outcomes in the FINEARTS-HF Trial: A Prespecified Secondary Analysis of FINEARTS-HF

Chimura M., et al, JAMA. 2026

Chimura M, 10 03 2026

Finerenone-Related Risk of Hypotension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Foa A., et al, JACC-HF. 2026

Foa A, 10 03 2026